Search Within

Nancy T Sklarin

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (9)
Groups
  1. Biostatistics Service (19)
  2. Breast Medicine Service (19)
  3. Department of Medicine (19)
  4. Epidemiology and Biostatistics (19)
  5. Solid Tumor Oncology Division (19)
  6. Survivorship Research (19)

More Groups

People
  1. Clifford Hudis (18)
  2. Monica Fornier (15)
  3. Andrew Seidman (13)
  4. Gabriella D'Andrea-Carlino (12)
  5. Larry Norton (12)
  6. Sujata Patil (12)

More People

Years
  1. 2021 (1)
  2. 2018 (1)
  3. 2015 (2)
  4. 2012 (3)
  5. 2011 (2)
  6. 2010 (4)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Clinical Cancer Research (3)
  3. Breast Cancer Research and Treatment (2)
  4. Cancer Research (2)
  5. Clinical Breast Cancer (2)
  6. Cancer (1)
Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (5)
  3. Elsevier Inc. (2)
  4. Springer (2)
  5. Wiley Blackwell (1)

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Journal Article

    Seidman, A. D.; Fornier, M. N.; Esteva, F. J.; Tan, L.; Kaptain, S.; Bach, A.; Panageas, K. S.; Arroyo, C.; Valero, V.; Currie, V.; more...
    Journal of Clinical Oncology (2001)

    Fulltext@MSK | Save
  • Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Theodoulou, M.; Moynahan, M. E.; Currie, V.; Moasser, M.; Sklarin, N.; Gilewski, T.; D'Andrea, G.; Salvaggio, R.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study
    Journal Article

    Hudis, C.; Fornier, M.; Riccio, L.; Lebwohl, D.; Crown, J.; Gilewski, T.; Surbone, A.; Currie, V.; Seidman, A.; Reichman, B.; more...
    Journal of Clinical Oncology (1999)

    Fulltext@MSK | Save